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Surgical site infections (SSI) affect 5 – 28 % of the patients who undergo breast surgery. In worst cases SSI can cause sepsis, delay of oncological treatments or death. Antibiotic prophylaxis (AP) is often used in these operations to reduce the 
risk of SSI’s, even though the research data is somewhat conflicting. It is also shown that microbial resistance to antibiotics is growing, and one of the reasons is the abuse of antibiotics. The primary purpose of this study was to evaluate the impact of AP in mastectomies, and secondarily to identify other risk factors for 
SSI’s. 
A retrospective medical record review of 300 consecutive patients who underwent mastectomy for oncological reasons between 1.5.2014 – 11.7.2016 was conducted. Patients were divided into two groups, where the prophylaxis group had received 1.5 g cefuroxime intravenously and the control group received no intervention. SSI incidences were compared between the two groups, and additionally other complications. Analysis about how certain potential risk factors 
managed to predict SSI’s and other complications was also performed. 
There were no statistically significant differences in the occurrence of SSI’s between the two groups. AP did not reduce the SSI rate in prophylaxis group when compared to the control (RR 1.3; 95% CI: 0.75–2.30, p=0.343). The most common microorganism isolated was Staphylococcus Aureus in both groups. Findings of this study does not support the routine use of antibiotic prophylaxis in mastectomy, and more studies about the subject are needed. 
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Background and objectives 
The rates of surgical site infections (SSI) following breast surgical procedures range 
from 5 to 28 % and prophylactic antibiotics have an important role in breast surgery as 
they have been proved to reduce the incidence of SSI’s. However, although the value of 
using preoperative prophylactic antibiotics in patients undergoing breast surgical 
procedures has been recently demonstrated, the outcomes are still conflicting, 
particularly in mastectomies. In contrast, inappropriate prescribing and abuse of 
antibiotics have shown to result in increased microbial resistance. 
The aim of this study is to evaluate the impact of antibiotic prophylaxis in mastectomy 
procedures and to quantify the possible vantage of prophylactic antibiotics on SSI 
incidence, in order to minimize the potential complications and antibiotic resistance and 
to improve the outcomes in a wide variety of clinical circumstances. 
  
Materials and methods 
Three-hundred consecutive patients underwent mastectomy for breast cancer between 
May 1st, 2014 and July 11th, 2016 were included into this study. Patients were divided 
into two groups on the basis of antibiotic prophylaxis. The prophylaxis group received 
1.5 g cefuroxime intravenously at anaesthesia (600 mg clindamycin, in case of specific 
allergy). The control group received no intervention. The primary outcome was the 
comparison of SSI incidences of the 2 groups. Secondary outcomes were specific 
wound healing complications at follow-up. 
 
Results 
No significant differences in demographic data were detected between the two groups. 
Intraoperative antibiotics did not reduce the SSI rate (23.2%) in the prophylaxis group 
when compared to the control [18.8%; relative risk (RR) 1.3; 95% CI: 0.75–2.30, 
p=0.343]. No adverse reactions were observed. 
The most common microorganism isolated was Staphylococcus aureus in both groups. 
Multivariate analysis revealed that prolonged operative time and hematoma occurrence 
were significant predictors of postoperative infection. 
 
Conclusions 
Antibiotic prophylaxis did not decrease SSI incidence after mastectomy for breast 
cancer surgery. This is somehow contrary to the previous literature and further studies 
are needed to identify patients who benefits most of antibiotic prophylaxis in 
mastectomies. 
   
1. Introduction 
Breast cancer is considered to be second most common cancer in the world, and the 
most common cause of cancer related death on women. [1] Surgery is essential part of 
breast cancer care for both curative and palliative treatments. Like every other surgical 
procedure, breast cancer surgery has its complications, and surgical site infections 
(SSI’s) are the most common ones [2]. Even though considered as clean operation, with 
a low chance of contamination and a relatively common procedure, the incidence of SSI 
ranges from 5 to 28 % according to the literature [3], while the typical incidence of 
surgical site infections in clean operations is about 3 % [4]. 
Infection prevention during breast cancer operations have a high priority because 
studies have shown that the patients affected by SSI’s have significantly higher 
mortality rates, and the overall treatment period ends up being longer and costlier. Other 
adverse effects of SSI’s are delay of the oncological treatments, readmissions, and poor 
cosmetic results. [5] 
Prophylactic antibiotics (PA’s) are used to combat these infections. Clinical trials 
suggest that the PA’s can reduce the incidence of SSI’s in breast operations [6, 7, 8], 
even though there is a lot of heterogeneity in the studies carried out about the subject. 
For example, from the eleven trials that were included in two major reviews [6, 8] only 
three studied the effect of AP in specifically mastectomies, although the rate of SSI’s 
greatly varies between different types of breast operations [9]. Also, a lot of conflicting 
results exist, especially when talking about total and radical mastectomies, and 
operations where the usage of drains are necessary [10, 11]. 
Prophylactic administration of antibiotics might be one reason of increasing microbial 
resistance and can cause adverse reactions, as well as Clostridium Difficile infections. 
[4, 12] There is also some evidence concerning that the usage of PA’s in breast surgery 
might conceal the symptoms of an infection instead of preventing it [13].   
Recognizing the specific risk factors for SSIs can be used to determine which patients 
benefit from the use of PA’s, this might be a proper way to reduce SSIs in breast cancer 
surgery [11, 14]. Some of the reported infection risk factors are older age, heavy alcohol 
intake, obesity, comorbidity, smoking, prolonged operation, transfusion and suboptimal 
use of drainage. All of the above are thought to be general risks of surgical infections, 
while breast cancer surgery has further risk factors like previous radiation treatment and 
chemotherapy, diagnostic biopsy procedures, or possible re-operation. Along with these, 
the lack of or suboptimal dosing of PA’s have been reported as a potential risk factor. 
[9, 15, 16] 
Because of varying outcomes between the studies about the effectiveness of PA’s 
particularly in mastectomies, and the increasing recognition of the adverse effects, there 
is not a clear consensus about PA administration. Further data about the effectiveness of 
PA specifically in mastectomies (modified radical mastectomies and total mastectomies 
without an axillary dissection) are needed to clarify this issue. 
The aim of this study is to evaluate the impact of antibiotic prophylaxis in mastectomy 
procedures and to quantify the possible vantage of prophylactic antibiotics on SSI 
incidence, in order to minimize the potential complications and antibiotic resistance and 
to improve the outcomes in a wide variety of clinical circumstances. 
We hypothesized that the administration of prophylactic antibiotic should lower the 
incidence of SSI’s in patients undergoing mastectomy for breast cancer.  
 
2. Materials and methods 
2.1. Participants 
A retrospective chart review of all consecutive patients who underwent MRM for 
oncological reasons between May 1st, 2014 and July 11th, 2016 in Turku University 
Hospital was performed. A change in our departments policy regarding to the use of 
antibiotics during that time made it possible to obtain enough patient data with and 
without the usage of prophylactic antibiotics. 
Patient inclusion criteria was that there was total mastectomy or radical mastectomy 
performed without any immediate reconstructions. Patients were identified through the 
hospitals surgical registry, and the data was retrieved from electronic databases. 
Patient exclusion criteria was that the mastectomy was performed as a prophylactic 
treatment, skin or nipple sparing mastectomy was performed or an immediate 
reconstruction was carried out. 
Data on demographics, comorbidities, and defect characteristics were collected 
meticulously from patient records. 
For the purpose of this study, patients were divided into two groups, depending if they 
had received prophylactic antibiotics. The prophylaxis group had received 1500mg 
cefuroxime or 600mg clindamycin intravenously at anesthesia, while the control group 
received no intervention. 
 
2.2. Procedures and techniques 
Mastectomy was performed to men and women who had been diagnosed with breast 
cancer that was not suited for local excision, or if the patient was unsuited for radiation 
therapy. 
Procedures used were modified radical mastectomy and total mastectomy with sentinel 
node biopsy. In the operations breast tissue was removed in one block, and the 
anatomical boundaries for the resection were the clavicle superiorly, the sternum 
medially, the inframammary fold inferiorly, and the latissimus along the pectoralis 
major fascia laterally. After that the axillary dissection was performed, unless sentinel 
node biopsy was free of cancer. 
 
2.3. Definitions and criteria 
The primary outcome measure was the surgical site infection (SSI) incidences in the 
two groups. Secondary outcomes included any surgical site occurrence (SSO), and 
specific complications such as fat or skin necrosis, wound dehiscence, hematoma, 
seroma. 
Obesity was defined as a body mass index greater than or equal to 30 kg/m2. Any 
patient who smoked tobacco within 1 month of surgery was considered an active 
smoker. 
Surgical-site occurrence was defined as any complication involving the operated breast. 
Infection (SSI) was defined as an infectious process (cellulitis/abscess) requiring 
treatment with intravenous or oral antibiotics with or without surgery. SSIs occurred 
within 30 days after the operation and with at least one of the following criteria; 
purulent drainage from the incision, organisms isolated from cultures obtained from 
fluids of the incision and one or more clinical symptoms of infection (pain, local 
swelling, redness, hot incision site) or diagnosis of SSI by attending physician. A 
positive microbiology swab result alone was not considered as enough evidence for 
infection. 
Wound dehiscence was defined as a skin breakdown with full-thickness skin separation 
extending over 2 cm with or without infection; skin necrosis involved clearly 
demarcated necrotic skin edges over 1 cm in width. Fat necrosis was considered as a 
palpable firmness 1 cm or greater in diameter that persisted beyond 3 months 
postoperatively. Hematoma and seroma are subcutaneous collections of blood or serous 
fluid, respectively, requiring percutaneous or operative drainage. 
Haemorrhage includes all cases of haemorrhage requiring blood transfusion (intra- or 
post-operatively), and those requiring intervention for post-operative haematoma 
(emergency exploration or delayed aspiration). 
Superficial wound infections which resolves without antibiotic treatment and minor 
wound dehiscence not requiring specialist dressing care is not included as 
complications. Scarring complications include hypertrophic or painful scars and any 
scars requiring surgical revision. 
Anaesthetic and medical complications: any anaesthetic (e.g. intubation or induction 
difficulty), respiratory or cardiovascular complications are included. 
 
2.4. Statistical Analysis 
Means and standard deviations were used to summarize continuous variables, whereas 
frequencies and percentages were used to present the categorical clinical characteristics. 
A multivariable logistic regression model was applied to identify the independent 
predictive factors for SSI. A backward model selection approach was used to select the 
predictive factors.  All tests were two-sided. A value of p < 0.05 was considered 
significant. IBM SPSS statistical software (IBM SPSS 25.0.0.1, Chicago, Illinois 60606, 
U.S.A) was used for all statistical analyses. 
 
3. Results 
A total of 300 patients were included in this study, prophylaxis group had 155 patients, 
while control group had 145. The only significant difference in the patient 
demographics between the groups was in the number of smokers (30.2 % in prophylaxis 
group and 19.3 % in control group, p=0.032). Other than that, no notable differences 
between the groups were found regarding to age, BMI, any comorbidity, diabetes, HTA, 
lipid disease, depression, use of omega-3 or BRCA mutation positivity (Table 1). 
Comparing the perioperative parameters between the two groups, significant difference 
was noted in three parameters; estimated blood loss (ml, mean ± SD) (113.5 ± 124.0 in 
prophylaxis group, 76.6 ± 63.9 in control group, p=0.004), duration of follow-up 
(months, mean ± SD) (27.0 ± 8.0 in prophylaxis group, 29.3 ± 7.4 in control group, 
p=0.011)  and in amount of sentinel node operations (51.0 % in prophylaxis group, 69.7 
% in control group, p=0.001). No notable differences were found regarding to operative 
time, resection weight, length of hospital stay or the number of double mastectomies or 
axillary dissections. [table 2] 
The overall incidence of SSI’s was 21 % (63/300), with 36 patients (23.3 %) from 
prophylaxis group and 27 (18.8 %) from the control group. There were no statistically 
significant differences in incidences of any, superficial or deep infections (p=0.343, 
p=0.980, p=0.507, respectively) between the two groups. Overall, no significant 
differences between the incidence of other postoperative complications (seroma, 
hematoma, wound dehiscence and skin necrosis) between the study groups was found 
either.  [table 3] 
In 23.8 % (15) of the cases where infection was diagnosed, microorganism was isolated. 
The most common microorganism isolated was Staphylococcus Aureus in both study 
groups. There were no statistical differences in culture results between the groups 
(p=0.793, Table 4). 
Univariate analysis showed significant variables associated to any infection occurrence: 
BMI (OR 3.3 per unit of change, CI 95% 1.4 – 4.9, p<0.001), breast resection weight 
(OR 58.6 per unit (g) of change, CI 95% 61.0 – 291.7, p=0.003), operative time (OR 
19.5 per unit (min) of change, CI 95% 11.9 – 27.0, p<0.001), hematoma (OR 10.1, CI 
95% 1.9 – 53.3, p=0.001) and seroma (OR 2.9, CI 95% 1.4 – 6.2, p=0.004). 
Multivariate analysis revealed that operative time (OR 1.0, CI 95% 1.0 – 1.1, 
p=0.005) and hematoma (OR 11.1, CI 95% 1.0 – 116.7, p=0.045) and the occurrence 
of hematoma requiring intervention were significant predictor of surgical site 
infection (Table 5). 
 
4. Discussion 
Antibiotic prophylaxis did not significantly reduce the rate of SSI. The incidence of 
SSI’s was 21%, which is roughly what is expected in mastectomies according to the 
literature [9], although smaller numbers such as 14.2% have also been reported [11]. 
From the variables that were associated to any infection occurrence in this study, BMI 
of 25 or over is a well-documented risk factor [17], and the size of breast resection, 
which was also associated to higher incidence of SSI’s, can be considered to be 
connected to the patients’ weight. Findings concerning hematoma and operative times 
as potential risk factors is also in line with recent studies [15]. 
Relatively few studies exist of the subject at hand, considering how large population is 
affected by breast cancer diagnosis and following treatments. A recent review (Jones 
2014) exists on the subject, including most of the major studies from the previous 
reviews, suggesting that the antibiotic prophylaxis reduces SSI’s in those involved in 
non-reconstructive breast cancer surgery. However, a lot of heterogeneity exists within 
the studies included in reviews, comparing different antibiotics, with different dosages 
and the lengths of follow-ups ranging from 5 to 42 days. Also, a variety of different 
operations were used in these studies and many of the trials group all types of breast 
surgeries together. Some of the studies included non-malignant cases, cosmetic 
procedures and surgeries that were some other than breast surgeries. With the 
knowledge that the incidences and potential risk factors are different in each types of 
operations [10], it seems wise to suggest that more studies are needed to determine the 
usefulness of antibiotic prophylaxis in mastectomies specifically. 
Previous prospective studies did not support the use of prophylactic antibiotics, [11, 13, 
14] while one retrospective study by Yetim et al. [18] suggested that antibiotic 
prophylaxis is justified, however, a collagen plus gentamycin sulphate sponge was 
inserted into the surgical wound instead of intravenous antibiotics as in other studies. 
Despite the methodological differences, the results of our study were in line with the 
previous studies. 
Current National guidelines for antibiotic use in breast surgery do not provide 
unisonous instructions on this issue, particularly AP usage in mastectomies for high risk 
patients. [20] 
The strength of this study includes the homogeneity of the procedures conducted, as 
well as consistent surgical technique, and the relatively large sample size compared to 
other studies about SSI incidences in mastectomies with the exclusion of local 
excisions. Included patients were consecutive, without withdrawing. Most of the 
patients had at least one control visit to the same department where surgery was 
performed, and follow-up was relatively long.  
The major limitation of this study was due to its retrospective nature. Surgeries were 
also conducted by 15 different surgeons with various level of experience, although 
similar dissection technique was used. 
There were also some significant differences in the study groups. Because the lack of 
proper randomization between the groups, and the chance that the operating surgeon 
could have prescribed the prophylaxis for the patients he or she felt were in the risk of 
SSI at the time, there is a possibility that the control group has more low-risk patients. 
That would also explain why there was significantly more smokers and blood loss in the 
prophylaxis group and could be the main reason for the results where more infections 
occurred in the prophylaxis group, albeit the amount not being statistically significant. 
Smaller amount of sentinel node operations in prophylaxis group could be because of 
more operations proceeding straight to the axillary dissection, which could have also 
been considered as a risk factor for SSI. However, no significant differences in axillary 
dissections between the groups were noted. Difference between the follow-up times 
exists because of the chronological sequence of the study groups and can be considered 
insignificant.  
A large part of the superficial infections was also diagnosed outside the hospital, by 
physicians with a varying amount of expertise in surgery. That could have inflated the 
numbers of superficial infections, since it’s not unprecedented to confuse the normal 
healing process of large surgical incision with an infection. 
From the base of this study, defining the impact of antibiotic prophylaxis in high-risk 
operations as well as further quantifying said risk factors should be focused on. There’s 
also some evidence that the bacterial profiles in healthy and cancerous breasts are 
different [21], which could be one of the reasons for different results in oncological and 
aesthetic surgery. 
With the evidence of this study and the other similar ones, it might be justified to 
reconsider the routine use of prophylactic antibiotic in clean non-reconstructive 
mastectomies. However, the patient specific and perioperative risk factors should still 
be considered and carrying out further studies about those factors leading to higher risk 
of SSI’s in controlled environment might be beneficial. The isolation of specific 
microbe from infected wound should be pursued, as it would help determining the 
antibiotics best suited for prophylaxis.  
 
5. Conclusions 
Findings of this retrospective study does not support the routine use of antibiotic 
prophylaxis in mastectomy, and more studies about the subject are needed. Even though 
this study has its limitations, the results are similar to the ones from previous studies. 
The exact identification of specific predictors for SSI in mastectomies might reduce the 
unnecessary use of antibiotics. 
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Table 1. Demographics of patients at time of study. 
 
  
 Prophylaxis Group 
(n = 155) Control Group (n = 145) p-value 
Age (mean ± SD) 67.5 ± 14.6 64.8 ± 15.3 0.108 
BMI (kg/m2, mean ± SD) 27.5 ± 6.1 26.4 ± 5.4 0.107 
Any comorbidity 114 (73.5%) 105 (72.4%) 0.825 
Diabetes 15 (9.7%%) 15 (10.3%) 0.847 
HTA 75 (48.4%) 63 (43.4%) 0.391 
Lipid disease 33 (21.3%) 26 (18.1%) 0.483 
Depression 6 (3.9%) 7 (4.8%) 0.684 
Smokers 45 (30.2%) 27 (19.3%) 0.032 
Omega-3 8 (5.5%) 4 (2.6%)  0.199 
BRCA 1 (0.6%) 4 (2.8%) 0.153 
Table 2. Comparison of perioperative parameters in the two groups of patients.  
 Prophylaxis Group (n = 
155) Control Group (n = 145) p-value 
Operative time (min, mean 
± SD) 97.0 ± 27.7 97.9 ± 28.5 0.787 
Double mastectomy 16 (10.3%) 8 (5.5%) 0.125 
Resection weight (g, mean ± 
SD) 683.2 ± 393.6 662.8 ± 370.8 0.663 
    
Estimated blood loss (ml, 
mean ± SD) 113.5 ± 124.0 76.6 ± 63.9 0.004 
Sentinel node 79 (51.0%) 101 (69.7%) 0.001 
Axillary dissection 103 (66.5%) 87 (60.0%) 0.247 
Hospital stay (days, mean ± 
SD) 3.59 ± 1.12 4.62 ± 3.20 0.081 
Follow-up (months, mean ± 
SD) 27.0 ± 8.0 29.3 ± 7.4 0.011 
  
Table 3. Postoperative complications.  
 Prophylaxis Group 
(n = 155) Control Group (n = 145) P-value* 
Complications 41 (26.5%) 37 (25.7%) 0.882 
    
Any infection 36 (23.2%) 27 (18.8%) 0.343 
Superficial infection 26 (16.8%) 24 (16.7%) 0.980 
Deep infection 14 (9.0%) 10 (6.9%) 0.507 
    
Seroma (requiring drainage) 113 (72.9%) 100 (69.0%) 0.453 
Hematoma (requiring intervention) 2 (1.3%) 5 (3.5%) 0.268 
Wound dehiscence 17 (11.0%) 13 (9.0%) 0.577 
Skin necrosis 4 (2.6%) 0 (0.0%) 0.124 
  
Table 4. Culture results in allocated study groups. 
 
 Prophylaxis Group 
(n = 155) Control Group (n=145) P-value* 
Microrganisms, n (%) 7 (4.5%) 8 (5.5%) 0.793 
S. aureus 3 (1.9%) 5 (3.4%)  
S. epidermidis 2 0  
C. perfringes 0 1  
S. betahemolyticus 0 1  
P. disiens 0  1  
St.lugdunensis 1  2   
Pseudomonas aerginosa 1 0  
    
  
Table 5. Significant univariate variables put into a multivariate model for any infection occurrence. 
 Odds ratio* 95% Confidence interval 
p-value 
    Any infection     Univariate Analysis   BMI 3.3 1.7-4.9 <0.001 Operative Time 19.5 11.9-27.0 <0.001 Breast resection weight 
58.6 61.0-291.7 0.003 
Hematoma 10.1 1.9-53.3 0.001 Skin necrosis 0.2 0.1-0.2 <0.001 Seroma 2.9 1.4-6.2 0.004 Any comorbidity 1.5 0.8-3.0 0.194  Multivariate Analysis   Operative time 1.0 1.0-1.1 0.005 Hematoma 11.1 1.0-116.7 0.045  
* For continuous variables and discrete variables, odds ratios represent degree of risk per unit of change. 
 
 
